Acutaas Chemicals Ltd Q1 FY27 Earnings Call: Reaffirms 25% Revenue Growth Guidance, Sets Rs. 1,000 Cr CDMO Target

Acutaas Chemicals Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Surges 59% YoY; Margins Expand Sharply

• Rs.329.7 crore revenue for Q1 FY 2026-2027, up 59.1% YoY, driven predominantly by the Pharma Intermediate segment.
• Pharma Intermediates revenue of Rs.292.7 crore (+76.5% YoY); Specialty Chemicals fell 10.6% YoY to Rs.37 crore as commodity phase-down offset BFC recovery.
• Gross profit Rs.190.9 crore, up 73% YoY; gross margin expanded 466 bps to 57.9% on higher pharma mix.
• EBITDA Rs.113.1 crore (margin 34.3%, +973 bps YoY) aided by gross margin expansion and operational efficiencies; PAT Rs.74.9 crore (margin 22.7%, +151 bps YoY).
• Net cash and equivalents at Rs.314 crore as of 30 June 2026; working capital days at 99 days (vs. 91 in Q4 FY 2025-2026) on higher inventory.
• Capacity utilisation: Sachin 83%, Ankleshwar 23%, Jagadia 55% in Q1 FY 2026-2027.
• Other income fell from Rs.11 crore (Q4 FY26) to Rs.1.8 crore due to a swing in forex — prior quarter included a positive Rs.10 crore forex fluctuation.

25% Revenue Growth Reaffirmed; CDMO Targets & Battery Ramp

• Management reaffirmed 25% revenue growth guidance for FY 2026-2027 with margins similar to FY 2025-2026 levels.
• CDMO revenue target of Rs.1,000 crore by FY 2027-2028; four validated products expected to contribute from H2 FY27, each with peak potential of Rs.50-100 crore.
• Battery chemicals (VC & FEC) plant commissioned with commercial supplies started in Q1; full capacity of 4,000 MT (2,000 MT each) targeted by FY 2028-2029.
• Electrolyte additive Phase 2 (third product) capex on schedule for completion by end of Q2 FY 2026-2027; contract in place, ramp-up expected from FY 2027-2028.
• Semiconductor R&D facility commissioned; product development started, with full capacity expected in 3–4 years ("...full capacity expected to be filled in 3–4 years (i.e., by FY2029-2030 to FY2030-2031)").
• Management developing 30–40 molecules annually for CDMO pipeline; new Sachin pilot plant to support expansion over the next 2–3 years.
• Commodity chemical rationalization completed for pharma intermediates in FY26; now underway for Specialty Chemicals in FY 2026-2027 to support margin improvement.

Q1 Margin Surge Not Seen as Run-Rate; FY27 Guidance Flat

• Q1 EBITDA margin of 34.3% is not the FY run-rate — management expects full-year FY 2026-2027 margin to be similar to FY 2025-2026 levels, not at the Q1 peak.
• Employee cost guided at ~Rs.150 crore for FY 2026-2027, inclusive of increments and one-time bonuses.
• Segment margins: Pharma Intermediates ~36%, Specialty Chemicals ~24%; battery chemicals are expected to carry lower margins than pharma or CDMO.
• Indichem business margins will benchmark against existing BFC product margins, not API or pharma intermediates — management called it "very preliminary" to quantify.
• Product mix shift over the next 3 years (pharma intermediates share from 87% to ~80% by FY 2028-2029) will pressure overall margins as lower-margin battery revenue grows.
• Other expenses in Q1 in line with prior quarters; savings from solar project and efficiencies expected to keep expenses similar for the rest of FY27.

Rs.56 Crore Spent in Q1; New Land & R&D Center Ahead

• Q1 FY27 capex of Rs.56 crore (Rs.15 crore at Indichem, Rs.41 crore at ACL site for battery chemicals, pilot plant, maintenance).
• FY 2026-2027 total capex: ~Rs.50 crore spillover from electrolyte additive and pilot plant plus Rs.40-45 crore maintenance; additional R&D center and land acquisition capex to be announced.
• New land parcel being acquired for future capacity expansion; Sachin pharma intermediate plant at capacity, Ankleshwar plant expected to fill by FY 2028-2029.
• Indichem semiconductor plant in Korea ahead of schedule, completion expected by end of Q3 FY 2026-2027; revenue contribution from FY 2027-2028.
• Electrolyte additive Phase 2 (third product) capex due by end of Q2 FY27; trial runs soon after, with contracted offtake enabling rapid ramp-up.

Focused on Additives; No API Entry; Concentrated CDMO Exposure

• No plans to enter electrolyte solution or LFP cathode segments — management committed to electrolyte additives only.
• No API manufacturing — policy of not competing with customers confirmed for FY 2026-2027 and beyond.
• CDMO revenue concentrated on a few molecules due to rapid growth in one product; management plans to de-risk over coming years through R&D pipeline expansion (no specific timeline).
• Darolutamide revenue opportunity tied to customer purchase orders — management declined to link to Bayer's improved $5 billion target or doubling of addressable patient pool.
• Management expects battery business to reach full capacity by FY 2028-2029 driven by robust demand, not supply constraints; a fourth product is in final contract stage.
• Revenue mix will shift with pharma intermediates declining to ~80% by FY 2028-2029 as battery and semiconductor ramp; overall margin impact is mixed due to lower battery margins.
• Management declined to provide margin guidance for 5 years citing dependence on future product mix between CDMO and newer businesses.

Pharma Intermediates Dominates; Specialty Chem in Transition

• Pharma Intermediates: Rs.292.7 crore in Q1 (+76.5% YoY) driven by top products and new molecule traction; segment margin ~36%.
• Specialty Chemicals: Rs.37 crore (−10.6% YoY) as commodity phase-down partially offset by BFC recovery; full-year FY27 revenue expected to not decline.
• CDMO within pharma intermediates growing faster than base business; management did not disclose revenue split.
• Battery chemicals (VC & FEC) capacity of 4,000 MT; commercial supplies started in Q1, ramp-up from Q2 through Q4 FY27.
• DMA filed for Johnson & Johnson/Caplita molecule; launch awaited (period unspecified).
• Product with patent expiries in CY 2026/2027 already gaining traction; sufficient capacity exists to meet demand.